TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03442465

Intervention type: BEHAVIORAL
Intervention: Musculoskeletal Tumor Society Score
Description: Clinician-reported global score. For lower extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, walking ability, gait, and necessary support. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. For upper extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, hand positioning, manual dexterity, and lifting ability. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. A total questionnaire score which is defined as the sum of the individual items divided by the maximum possible score (5 times the number of items) may also be computed. It is represented as a percentage from 0 - 100%.

Intervention type: BEHAVIORAL
Intervention: Musculoskeletal Tumor Society Score
Description: Clinician-reported global score. For lower extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, walking ability, gait, and necessary support. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. For upper extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, hand positioning, manual dexterity, and lifting ability. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. A total questionnaire score which is defined as the sum of the individual items divided by the maximum possible score (5 times the number of items) may also be computed. It is represented as a percentage from 0 - 100%.

Intervention type: BEHAVIORAL
Intervention: Timed Get Up and Go Test
Description: Validated functional measurement, for lower extremities only. The patient is observed and timed while s/he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. The test predicts the patient's ability to go outside alone safely and quantifies functional mobility. The test requires no special equipment and will take less than one minute to complete.
Study: NCT00085969

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.08 mL once daily
Description: Subcutaneously injected, 0.08 mL, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B - Exenatide 10 mcg twice daily
Description: Subcutaneously injected, 10 mcg (0.04 mL), twice daily
Study: NCT04315142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental TTNS
Description: 30-minute TTNS intervention is performed 2 days a week during a treatment period of 6 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TTNS
Description: 30-minute sham intervention is performed 2 days a week during a treatment period of 6 weeks
Study: NCT04460794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ballet-inspired workouts
Description: 8 weeks, delivered by volunteers with a self-directed resource package

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care and general recommendations on basic stretching and leg exercises for stroke survivors
Study: NCT02213107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide and Dutasteride or finasteride
Description: Use of either two oral drugs together~1. Enzalutamide by mouth daily and dutasteride by mouth daily or~2. Enzalutamide by mouth daily and finasteride by mouth daily
Study: NCT04517799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: While in the intervention arm subjects will receive EPIDIOLEX, an oral purified CBD solution developed by GW Pharmaceuticals. The formulation is a 100 mg/mL solution, which allows for easy dose titration and administration even to young children. EPIDIOLEX is naturally-derived CBD, and has been found to have a purity of over 98%. The solution includes a sweetener to make it palatable. Dosing is dependent upon each subject's weight.~The dosage will be titrated over time as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo oral solution
Description: GW has developed a placebo that is identical in color and taste, and will be administered in the same volume as the CBD, so that parents and investigators should not be able to detect differences between the 2 treatments. Dosing is dependent upon each subject's weight.~The dosage will be titrated as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change.
Study: NCT03847090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reloxaliase
Description: Reloxaliase 2 capsules, orally, with each meal/snack, 3 to 5 times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day
Study: NCT00609973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacin 500 mg oral bid for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid for 6 months
Study: NCT02216851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Perlane
Description: Intradermal injection
Study: NCT03242733

Intervention type: OTHER
Intervention: Ultrasound assessment of gastric contents
Description: Ultrasound assessment of gastric contents is performed in fasted elderly patients for hip fracture surgery.
Study: NCT03399123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tidal volume
Description: After General anesthesia, patients that during volume control mode of mechanical ventilation in experimental group, we take low tidal volume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tidal volume
Description: After General anesthesia, patients that during volume control mode of mechanical ventilation in experimental group, we take low tidal volume.
Study: NCT02106559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: porfimer sodium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo tumor resection and/or radical pleurectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo PDT
Study: NCT03309059

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: water and soap
Description: Use of soap and water in the area and subsequent diaper placement disposable.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zinc oxide
Description: Use of soap and water sanitation and application of zinc oxide.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Irritant Barrier Film
Description: Use of soap and water hygiene and application of Non Irritant Barrier Film.
Study: NCT01447472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
Study: NCT04294238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
Study: NCT02453191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene Laherparepvec

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
Study: NCT03412890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix 40-mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: Capsule containing co-formulated tablet of E2 (1 mg) and NETA (0.5 mg) administered orally once daily
Study: NCT02172599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit-stand workstation provision
Description: The research compares the effects of a sit-stand workstation only and a multi-component sit-stand workstation intervention including individual and organisation-level approaches, with usual office-based working practice (no sit-stand workstation) over 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit-stand workstation provision
Description: The research compares the effects of a sit-stand workstation only and a multi-component sit-stand workstation intervention including individual and organisation-level approaches, with usual office-based working practice (no sit-stand workstation) over 12 months.
Study: NCT04275414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min
Study: NCT02526394

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine
Description: Meningococcal vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine
Description: Meningococcal vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine
Description: Meningococcal vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine
Description: Meningococcal vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine
Description: Meningococcal vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine
Description: Meningococcal vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine
Description: Meningococcal vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine
Description: Meningococcal vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertussis containing vaccine
Description: Pertussis containing vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertussis containing vaccine
Description: Pertussis containing vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertussis containing vaccine
Description: Pertussis containing vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertussis containing vaccine
Description: Pertussis containing vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertussis containing vaccine
Description: Pertussis containing vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertussis containing vaccine
Description: Pertussis containing vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertussis containing vaccine
Description: Pertussis containing vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertussis containing vaccine
Description: Pertussis containing vaccination
Study: NCT00513864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: one time dose - 0.3mg/kg PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: one time dose - 0.3mg/kg PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine
Description: one time dose - 2mg/kg PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine
Description: one time dose - 2mg/kg PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: one time dose - 0.15mg/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: one time dose - 0.15mg/kg IV
Study: NCT03428555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Care Pathway
Description: The intervention is a integrated care pathway based on the NICE Clinical Practice Guidelines and measurement-based care in the form of a flow chart. Each decision point on the pathway is guided by results of self-report measures for depression (the Mood and Feelings Questionnaire), functional impairment (Columbia Impairment Scales) and family functioning (the McMaster Family Assessment Device). The results of these scales and protocol recommendations are fed back to the patients, families and clinicians in order to make further treatment decisions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment As Usual represents what clinicians would typically do when presented with an adolescent with depression. There is no algorithm provided to guide clinical decision-making and no systematic measurement-based care.
Study: NCT00483509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: iv q3W 0.8 mcg/sqm NGR-hTNF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
Study: NCT00185900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.
Study: NCT02983942

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Routine diet
Description: Routine diet is given without blood ketone requirement
Study: NCT02957123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal auto-M2-BFs
Description: Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
Study: NCT02965976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Undergo esophagectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Undergo esophagectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00305279

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: Dietary
Study: NCT03342781

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal oxygen therapy
Description: Oxygen therapy using a high-flow nasal cannula (HFNC) is a high-flow oxygen delivery system that enhances the efficiency of respiration by using high flow rates to clear dead space and provide fresh oxygen. This system supplies oxygen at a high flow rate through a loose nasal cannula.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diffuser oxygen mask
Description: diffuser mask is a low-flow delivery system, which is capable of delivering up to 90% of the fraction of inspired oxygen (FiO2) with low CO2 retention. In this system, the FiO2 can be adjusted by modifying the flow velocity to deliver the quantity of oxygen that the patient requires. Oxygen is supplied to the patient in a jet that flows from a device mounted on the oxygen mask. This ensures that a high concentration of oxygen is provided at a low flow rate.
Study: NCT01890902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen 10% Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00790829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nicotine patch
Description: Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
Study: NCT04776941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Read positive messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Write about positive experiences

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Write about neutral topics

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Read neutral messages
Study: NCT00085969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C - Exenatide 10 mcg once daily
Description: Subcutaneously injected, 10 mcg (0.04 mL), once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 20 mcg once daily
Description: Subcutaneously injected, 20 mcg (0.08 mL), once daily
Study: NCT06365333

Intervention type: PROCEDURE
Intervention: Fluoroscopic-guided air-enema reduction (FGAR)
Description: A hand-held pump facilitated the delivery of atmospheric air, while pressure was monitored using a digital gauge. A two-way Foley's balloon catheter, ranging from 18oF to 24oF in diameter depending on age, was inserted rectally to introduce air. Following insertion, the balloon was filled with 10cc of saline to prevent air leakage, with patient immobilization ensured by leg straps and hand positioning above the head for abdominal exposure. Under intermittent fluoroscopy, the surgeon operated the pump with the right hand, inflating the catheter to 80 to 120 mmHg, simultaneously palpating the intussusceptum with the left hand, employing a deep gliding motion for deep and fixed cases. Successful reduction, indicated by air entry into the small bowel, was confirmed under fluoroscopy, with a subsequent brief rotating abdominal massage ensuring uniform air distribution throughout the small intestine, confirming complete reduction.
Study: NCT04127136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary obesity management therapy
Description: In twenty weeks, trainings by the physician, dietitian, psychologist and physiotherapist are conducted about medical information about obesity, using the technology to aid weight loss, what, when, how and why to eat, nutrition groups, ration management, water consumption, self-awareness, stress management, obesity and the association between the psychological processes, warming up and mobilization, correct stance and posture, and adequate physical activity. In addition to group meetings, in monthly individual meetings, the progress of the patients are evaluated.
Study: NCT03525977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia iliaca block arm
Description: The fascia iliaca block will be performed by the anesthesiologist on call
Study: NCT03040583

Intervention type: OTHER
Intervention: No intervention
Description: Patients data will be collected during their disease follow-up
Study: NCT02545374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT03050463

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood and saliva sample collection

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood and saliva sample collection

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood and saliva sample collection
Study: NCT02137421

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol (3, 4´, 5 trihydroxystilbene)
Description: Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol (3, 4´, 5 trihydroxystilbene)
Description: Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)
Study: NCT06093360

Intervention type: PROCEDURE
Intervention: flapless surgery
Description: Implant-supported restorations were unscrewed and modified if necessary (biofilm control). All the restorations were relocated at the end of each intervention session. After local anesthesia, a periodontal ultrasonic stainless-steel tip was used for supra- and sub-mucosal mechanical debridement. Next, a Columbia 4R/4L curette was used around the implant in a circular motion until a bone exposure of 2-3 mm was achieved. Mucosal curettage was simultaneously performed to remove the granulation tissue. After obtaining access to the implant surface, ultrasonic instrumentation was repeated and air polishing with an erythritol powder was applied submucosally with the aim of a periodontal probe. Hydrogen peroxide 3% was used to irrigate the implant surface for 2 minutes, followed by a rinse with saline. Oral hygiene instructions were given. Systemic antibiotics, when prescribed, were metronidazole or azithromycin
Study: NCT00305279

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: Dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: Dietary
Study: NCT00001082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: 500 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: 500 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil
Description: 120 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil placebo
Description: Oral placebo tablet taken daily
Study: NCT03099356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 100 mg, PO, days 1-5 and 15-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus 4 mg, PO, days 1-28
Study: NCT03486639

Intervention type: OTHER
Intervention: IPSS questionnaire
Description: IPSS is an 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of patients with lower urinary tract symptoms. It was validated for both genders.
Study: NCT04215328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed-Meal
Description: Per 250ml bottle: 220 calories, protein 9g, carbohydrate 33g (15g sugar), fat 6g, sodium 190mg, potassium 390mg; 500mLs by tube daily in 4 doses

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Electrolyte Solution
Description: Electrolyte Solution 500mLs by tube daily in 4 doses